maralixibat: Clinical Trials

19 trials of maralixibat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 4 recruiting, 2 not yet recruiting, 1 active not recruiting. 10 Phase 2, 5 Phase 3, 1 Phase 1, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 210Completed 7, Not yet recruiting 2, Recruiting 1
Phase 35Completed 2, Active not recruiting 1, Recruiting 1, Withdrawn 1
Phase 11Completed 1
Phase 41Recruiting 1

Follow maralixibat: new trials by email Literature Review of maralixibat trials Research Report on maralixibat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)
Maralixibat - Intrahepatic Cholestasis of Pregnancy
Phase 2Not yet recruitingMirum Pharmaceuticals, Inc.152027-01-152026-09-16
Maralixibat for Intrahepatic Cholestasis of Pregnancy
Maralixibat - Intrahepatic Cholestasis of Pregnancy
Phase 2Not yet recruitingImperial College London282026-04-012026-02-05
A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
Maralixibat - Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC)
RecruitingTakeda502026-01-132026-02-20
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
Livmarli Oral Product - Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Phase 4RecruitingMirum Pharmaceuticals, Inc.2302025-09-252026-06-23
Maralixibat in Patients With Cystic Fibrosis and Constipation
Maralixibat 9.5 MG/ML [Livmarli] - Constipation Chronic Idiopathic, Cystic Fibrosis
Phase 2 / Phase 3RecruitingChildren's Hospital Los Angeles202025-04-092026-04-21
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
Maralixibat, Placebo - Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Phase 3Active not recruitingMirum Pharmaceuticals, Inc.902024-10-142026-11-13
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
Livmarli - Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
RecruitingMirum Pharmaceuticals, Inc.702023-09-212026-11-13
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Maralixibat - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome
Phase 2CompletedMirum Pharmaceuticals, Inc.272021-09-092026-06-02
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
Maralixibat, Placebo - Biliary Atresia
Phase 2CompletedMirum Pharmaceuticals, Inc.752021-07-082025-03-19
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
Maralixibat - Cholestatic Liver Disease
Phase 2CompletedMirum Pharmaceuticals, Inc.522020-01-162025-12-08
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
Maralixibat - Progressive Familial Intrahepatic Cholestasis (PFIC)
Phase 3CompletedMirum Pharmaceuticals, Inc.842020-01-082026-06-23
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Maralixibat, Placebo - Progressive Familial Intrahepatic Cholestasis (PFIC)
Phase 3CompletedMirum Pharmaceuticals, Inc.932019-07-092023-12-11
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Maralixibat, Placebo - Progressive Familial Intrahepatic Cholestasis (PFIC)
Phase 3WithdrawnMirum Pharmaceuticals, Inc.2018-10-252019-03-18
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
Placebo, Maralixibat, Volixibat - Healthy Volunteers
Phase 1CompletedMirum Pharmaceuticals, Inc.842015-06-012019-04-04
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
LUM001 (Maralixibat) - Alagille Syndrome
Phase 2CompletedMirum Pharmaceuticals, Inc.342015-03-162021-07-01
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
LUM001 (Maralixibat), Placebo - Alagille Syndrome
Phase 2CompletedMirum Pharmaceuticals, Inc.312014-10-282021-07-14
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
LUM001 (Maralixibat) - Progressive Familial Intrahepatic Cholestasis (PFIC)
Phase 2CompletedMirum Pharmaceuticals, Inc.332014-03-012023-10-23
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
LUM001 (Maralixibat) - Alagille Syndrome
Phase 2CompletedMirum Pharmaceuticals, Inc.192013-12-202021-11-19
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
maralixibat - Alagille Syndrome
Approved for marketingMirum Pharmaceuticals, Inc.2021-10-20

Conditions studied

Alagille Syndrome (8)  ·  Cholestasis, progressive familial intrahepatic 1 (8)  ·  Bile Duct Diseases (7)  ·  Cholestasis (7)  ·  Liver Diseases (7)  ·  Biliary Tract Diseases (6)  ·  Pruritus (5)  ·  Digestive System Diseases (4)  ·  Biliary Atresia (2)  ·  Intrahepatic Cholestasis of Pregnancy (2)  ·  Cholangitis, Sclerosing (1)  ·  Cholestasis, Intrahepatic (1)  ·  Congenital Abnormalities (1)  ·  Cystic Fibrosis (1)

Sponsors

Mirum Pharmaceuticals, Inc. (16)  ·  Children's Hospital Los Angeles (1)  ·  Imperial College London (1)  ·  Takeda (1)

Countries

United States (12)  ·  United Kingdom (10)  ·  France (8)  ·  Poland (8)  ·  Belgium (6)  ·  Canada (5)  ·  Germany (5)  ·  Brazil (4)  ·  Italy (4)  ·  Spain (4)  ·  Lebanon (3)  ·  Mexico (3)  ·  Singapore (3)  ·  Argentina (2)  ·  Australia (2)

Top investigators

Catherine Williamson, MD (1)  ·  Jaya Punati, MD (1)

Results publications

PMID 42002216, PMID 34755627, PMID 35507739, PMID 36096175, PMID 38723644

NIH funding

2017 (1), 2019 (1)